18 related articles for article (PubMed ID: 18661869)
1. Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges.
Wen H; Jung H; Li X
AAPS J; 2015 Nov; 17(6):1327-40. PubMed ID: 26276218
[TBL] [Abstract][Full Text] [Related]
2. Treatment with Tie2-siRNA in combination with carboplatin suppresses the growth of Ishikawa human endometrial carcinoma cell xenografts
Guo F; Xun Q; Zhou H
Oncol Lett; 2013 Jun; 5(6):1777-1782. PubMed ID: 23833640
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic genistein inhibits VEGF-induced endothelial cell activation by decreasing PTK activity and MAPK activation.
Yu X; Zhu J; Mi M; Chen W; Pan Q; Wei M
Med Oncol; 2012 Mar; 29(1):349-57. PubMed ID: 21132400
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
Yang K; Wang YJ; Chen XR; Chen HN
Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
[TBL] [Abstract][Full Text] [Related]
5. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin.
Kim JH; Lee SK; Ki MH; Choi WK; Ahn SK; Shin HJ; Hong CI
Int J Pharm; 2004 Mar; 272(1-2):79-89. PubMed ID: 15019071
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
Katanasaka Y; Ida T; Asai T; Shimizu K; Koizumi F; Maeda N; Baba K; Oku N
Cancer Lett; 2008 Nov; 270(2):260-8. PubMed ID: 18555591
[TBL] [Abstract][Full Text] [Related]
7. Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
Ogawara K; Abe S; Un K; Yoshizawa Y; Kimura T; Higaki K
J Pharm Sci; 2014 Aug; 103(8):2464-9. PubMed ID: 24985750
[TBL] [Abstract][Full Text] [Related]
8. Effect of 2-hydroxypropyl-beta-cyclodextrin on the solubility, stability, and pharmacological activity of the chemical delivery system of TRH analogs.
Wu WM; Wu J; Bodor N
Pharmazie; 2002 Feb; 57(2):130-4. PubMed ID: 11878189
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel/beta-cyclodextrin complexes for hyperthermic peritoneal perfusion - formulation and stability.
Bouquet W; Ceelen W; Fritzinger B; Pattyn P; Peeters M; Remon JP; Vervaet C
Eur J Pharm Biopharm; 2007 Jun; 66(3):391-7. PubMed ID: 17240125
[TBL] [Abstract][Full Text] [Related]
10. Development of an intravenous formulation of SU010382 (prodrug of SU5416, an anti-angiogenesis agent).
Sistla A; Kertelj A; Shenoy N
PDA J Pharm Sci Technol; 2008; 62(3):200-10. PubMed ID: 18661869
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
